Falk AT, et al. - Given the impact of anti-PD-1/PD-L1 inhibitors on lung adenocarcinomas (LADCs) with KRAS mutations is debatable, researchers assessed the link between specific mutant KRAS proteins and the immune infiltrates with the outcome of patients with LADCs. A significantly higher PD-L1 expression was detected in tumors harboring mutant KRAS-G12 V vs other tumors. An association was evident between high PD-L1 expression in tumor cells and improved overall survival (OS) in KRAS mutant patients, but not in the wild-type (WT) population. Overall, findings showed a heterogeneous impact of KRAS mutational status on immune microenvironment and survival of LADC patients. Patient stratification for immunotherapy should be done by taking into account specific mutant KRAS variants expressed by the tumor.